KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
KalVista Awarded UK PIM Designation for Sebetralstat
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
KalVista Pharmaceuticals to Present HAE Attack Journey Data
KalVista Announces Appointment of Benjamin L. Palleiko as CEO